Phase 3 Trial Progress: Recent discussions on X about Viking Therapeutics (VKTX) have centered on the rapid progress of its Phase 3 VANQUISH trial for the injectable obesity drug VK2735. Many users are impressed by the swift enrollment pace, viewing it as a potential catalyst for future stock movement. There’s anticipation for topline data, which could significantly impact market perception.
Oral Drug Data Buzz: Another hot topic on X is the Phase 2 results for the oral version of VK2735, with reported weight loss figures sparking excitement. While some highlight the drug’s efficacy and safety at certain doses, others note concerns over tolerability at higher levels. The mixed feedback has fueled lively debates on the stock’s prospects.
Analyst Updates and Insider Activity: Posts on X also mention recent analyst upgrades and price target increases for VKTX, reflecting optimism in some quarters. However, news of significant insider selling by executives has raised eyebrows among users. This blend of positive and cautious takes keeps the conversation dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
Viking Therapeutics Insider Trading Activity
Viking Therapeutics insiders have traded $VKTX stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- CHARLES A JR ROWLAND sold 60,000 shares for an estimated $2,134,278
- BRIAN LIAN (President & CEO) has made 0 purchases and 2 sales selling 65,878 shares for an estimated $2,112,555.
- MARIANNA MANCINI (Chief Operating Officer) has made 0 purchases and 2 sales selling 10,451 shares for an estimated $334,964.
- GREG ZANTE (Chief Financial Officer) has made 0 purchases and 2 sales selling 10,451 shares for an estimated $334,908.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Viking Therapeutics Hedge Fund Activity
We have seen 214 institutional investors add shares of Viking Therapeutics stock to their portfolio, and 172 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. removed 1,648,628 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $43,688,642
- FMR LLC removed 1,427,440 shares (-12.7%) from their portfolio in Q2 2025, for an estimated $37,827,160
- TWO SIGMA INVESTMENTS, LP added 1,261,369 shares (+2406.5%) to their portfolio in Q2 2025, for an estimated $33,426,278
- TWO SIGMA ADVISERS, LP added 1,091,428 shares (+inf%) to their portfolio in Q2 2025, for an estimated $28,922,842
- ALLIANCEBERNSTEIN L.P. removed 1,013,657 shares (-97.5%) from their portfolio in Q2 2025, for an estimated $26,861,910
- CITADEL ADVISORS LLC removed 778,115 shares (-47.1%) from their portfolio in Q2 2025, for an estimated $20,620,047
- MILLENNIUM MANAGEMENT LLC added 689,292 shares (+272.8%) to their portfolio in Q2 2025, for an estimated $18,266,238
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Viking Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $VKTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 10/29/2025
- JP Morgan issued a "Overweight" rating on 10/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/29/2025
- Raymond James issued a "Strong Buy" rating on 07/24/2025
To track analyst ratings and price targets for Viking Therapeutics, check out Quiver Quantitative's $VKTX forecast page.
Viking Therapeutics Price Targets
Multiple analysts have issued price targets for $VKTX recently. We have seen 7 analysts offer price targets for $VKTX in the last 6 months, with a median target of $102.0.
Here are some recent targets:
- Edward Nash from Canaccord Genuity set a target price of $106.0 on 10/29/2025
- Hardik Parikh from JP Morgan set a target price of $75.0 on 10/24/2025
- Michael Ulz from Morgan Stanley set a target price of $102.0 on 10/23/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $102.0 on 09/29/2025
- Justin Zelin from BTIG set a target price of $125.0 on 09/22/2025
- David Lebowitz from Citigroup set a target price of $38.0 on 07/24/2025
- Ryan Deschner from Raymond James set a target price of $122.0 on 07/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
